Valuation: Evotec

Market Cap 614M 699M 571M 524M 984M 67.32B 1B 6.78B 2.65B 33.09B 2.62B 2.57B 114B P/E 2026 *
-4.01x
P/E 2027 * -10x
Enterprise Value 655M 746M 610M 559M 1.05B 71.87B 1.07B 7.24B 2.83B 35.33B 2.8B 2.74B 122B EV / Sales 2026 *
1.09x
EV / Sales 2027 * 0.98x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+8.33%-.--% - - 700M
+1.07%-3.49%-3.25%+12.87% 46.35B
+0.25%+1.65%+408.41%+629.49% 40.13B
-0.27%+4.45%+9.93%+66.92% 36.33B
+0.35%+0.87%+3.60%-8.81% 34.6B
+3.14%+1.02%+3.37%+38.15% 26.77B
-0.73%+11.84%+31.97%+143.53% 16.91B
+0.47%-2.74% - - 16.66B
+0.42%-5.52%+0.76%+8.50% 13.05B
-2.68%-2.49%-15.00%-31.68% 13.05B
Average +1.04%+0.99%+54.97%+107.37% 27.09B
Weighted average by Cap. +0.48%+1.10%+75.57%+137.02%

Financials

2026 *2027 *
Net sales 600M 683M 558M 512M 962M 65.75B 976M 6.62B 2.59B 32.32B 2.56B 2.51B 112B 736M 838M 685M 628M 1.18B 80.71B 1.2B 8.13B 3.18B 39.68B 3.15B 3.08B 137B
Net income -147M -168M -137M -126M -236M -16.14B -240M -1.63B -635M -7.93B -629M -615M -27.43B -47.45M -54.03M -44.13M -40.5M -76.09M -5.2B -77.26M -524M -205M -2.56B -203M -198M -8.84B
Net Debt 41.5M 47.25M 38.59M 35.42M 66.54M 4.55B 67.57M 458M 179M 2.24B 177M 174M 7.73B 105M 120M 97.8M 89.75M 169M 11.53B 171M 1.16B 454M 5.67B 449M 440M 19.6B
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.454EUR
Average target price
4.900EUR
Spread / Average Target
+41.86%

Quarterly revenue - Rate of surprise